Interest of Ascorbic Acid in the Management of Pneumonia in Elderly People Hospitalized. (NCT02186158) | Clinical Trial Compass
TerminatedPhase 2
Interest of Ascorbic Acid in the Management of Pneumonia in Elderly People Hospitalized.
Stopped: target number of inclusion not reached
France9 participantsStarted 2015-02
Plain-language summary
Pneumonia is the second common infection and its risk increases for elderly. In this population, it is the first cause of mortality by infections, and source of many complications. Geriatric studies had shown the high prevalence of ascorbic acid 's deficiency, especially in older hospitalized people. It is well known that vitamin C is one of the key of the immune system, it has a scavenger's role in case of aggression like sepsis. A Cochrane database published in 2013 analyzed the impact of vitamin C for preventing and treating pneumonia. Two randomized studies showed a benefit on respiratory symptoms for patients treated by vitamin C, and for one of those studies it was noted a significant reduction of mortality. The main objective of our study is first to determine the impact on respiratory symptoms of an adjuvant treatment by vitamin C for the management of pneumonia in older people hospitalized, and then evaluate its impact on functional status.
Who can participate
Age range
75 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* people aged ≥ 75 years old
* pneumonia's symptoms according to the SPILF (Société de Pathologie Infectieuse de Langue Française) :
* cough
* at least one respiratory sign : dyspnea, chest pain, wheezing, and local signs at the auscultation
* at least one general sign suggesting an infection : fever, sweat, headache, sore joints, common cold
* pneumonia's symptoms developed between the admission's date in the unit care and the seventh day included
Exclusion Criteria:
* palliative care's patients
* patients with deglutition's disorders
* patients who can't be on a drip
* antibiotherapy since more one day
* other concomitant infection(s)
* patients who can't make their own transfer 15 days ago
* patients who have a NYHA score at IV 15 days ago
* patients with contraindication to a vitamin C treatment : hemochromatosis, oxalo-calcic lithiasis antecedent, G6PD deficit (Glucose 6 Phosphate Dehydrogenase), and treatment by Deferoxamine
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Difference in the NYHA score between d-15 and d4 after treatment initiation
Timeframe: 4 days after randomisation/treatment initiation